Settlement Announced in Generic Drug Price Inflation Case
What happened
A settlement plan was approved in the U.S. District Court for the District of Connecticut involving several generic drug manufacturers. The companies, including Apotex and Glenmark, are accused of conspiring to inflate prices for various generic prescription and over-the-counter medicines. The settlement covers purchases made between May 2009 and December 2019, and consumers can seek refunds for eligible purchases.
From journal-news.com
Why it matters
The case originated from a coalition of states pursuing antitrust actions against the manufacturers. The settlement involves $96.5 million in funds to be distributed. The resolution impacts the market structure and pricing of generic pharmaceuticals.
From journal-news.com
Who's involved
- ApotexGeneric drug manufacturer involved in the antitrust settlement.
- Glenmark PharmaceuticalsGeneric drug manufacturer involved in the antitrust settlement.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- ApotexSpeculative
Apotex could face financial liability stemming from the antitrust settlement regarding generic drug pricing.
- Glenmark PharmaceuticalsSpeculative
Glenmark Pharmaceuticals could face financial liability stemming from the antitrust settlement regarding generic drug pricing.
Keep exploring
The entities involved
-
Apotex
Canadian private pharmaceutical company
-
Connecticut
state of the United States of America
-
Andy Wilson
Australian footballer
Nothing else this week.